PL3898638T3 - Krystaliczne formy inhibitora par4 - Google Patents
Krystaliczne formy inhibitora par4Info
- Publication number
- PL3898638T3 PL3898638T3 PL19842497.0T PL19842497T PL3898638T3 PL 3898638 T3 PL3898638 T3 PL 3898638T3 PL 19842497 T PL19842497 T PL 19842497T PL 3898638 T3 PL3898638 T3 PL 3898638T3
- Authority
- PL
- Poland
- Prior art keywords
- crystalline forms
- par4 inhibitor
- par4
- inhibitor
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783223P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/067717 WO2020132381A1 (en) | 2018-12-21 | 2019-12-20 | Crystalline forms of a par4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3898638T3 true PL3898638T3 (pl) | 2023-12-04 |
Family
ID=69187955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19842497.0T PL3898638T3 (pl) | 2018-12-21 | 2019-12-20 | Krystaliczne formy inhibitora par4 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US12129264B2 (pl) |
| EP (1) | EP3898638B1 (pl) |
| JP (1) | JP7473554B2 (pl) |
| KR (1) | KR20210109559A (pl) |
| CN (3) | CN121021533A (pl) |
| AU (2) | AU2019403348B2 (pl) |
| BR (1) | BR112021011688A2 (pl) |
| CA (1) | CA3124100A1 (pl) |
| CL (1) | CL2021001590A1 (pl) |
| CO (1) | CO2021008043A2 (pl) |
| DK (1) | DK3898638T3 (pl) |
| EA (1) | EA202191760A1 (pl) |
| ES (1) | ES2964404T3 (pl) |
| FI (1) | FI3898638T3 (pl) |
| HR (1) | HRP20231527T1 (pl) |
| HU (1) | HUE064830T2 (pl) |
| IL (2) | IL320212A (pl) |
| LT (1) | LT3898638T (pl) |
| MX (1) | MX2021007417A (pl) |
| MY (1) | MY206303A (pl) |
| PE (1) | PE20211963A1 (pl) |
| PL (1) | PL3898638T3 (pl) |
| PT (1) | PT3898638T (pl) |
| RS (1) | RS64900B1 (pl) |
| SA (1) | SA521422311B1 (pl) |
| SG (1) | SG11202106561RA (pl) |
| SI (1) | SI3898638T1 (pl) |
| SM (1) | SMT202300417T1 (pl) |
| WO (1) | WO2020132381A1 (pl) |
| ZA (1) | ZA202105115B (pl) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2841437T (pt) | 2012-04-26 | 2017-09-28 | Univ Montreal | Derivados de imidazotiadiazol e imidazopirazina como inibidores de recetor 4 ativado por protease (par4) para o tratamento de agregação plaquetária |
-
2019
- 2019-12-20 WO PCT/US2019/067717 patent/WO2020132381A1/en not_active Ceased
- 2019-12-20 US US17/415,237 patent/US12129264B2/en active Active
- 2019-12-20 MY MYPI2021003475A patent/MY206303A/en unknown
- 2019-12-20 HU HUE19842497A patent/HUE064830T2/hu unknown
- 2019-12-20 DK DK19842497.0T patent/DK3898638T3/da active
- 2019-12-20 CN CN202510888947.9A patent/CN121021533A/zh active Pending
- 2019-12-20 AU AU2019403348A patent/AU2019403348B2/en active Active
- 2019-12-20 MX MX2021007417A patent/MX2021007417A/es unknown
- 2019-12-20 SG SG11202106561RA patent/SG11202106561RA/en unknown
- 2019-12-20 BR BR112021011688-5A patent/BR112021011688A2/pt unknown
- 2019-12-20 IL IL320212A patent/IL320212A/en unknown
- 2019-12-20 IL IL284222A patent/IL284222B2/en unknown
- 2019-12-20 ES ES19842497T patent/ES2964404T3/es active Active
- 2019-12-20 EP EP19842497.0A patent/EP3898638B1/en active Active
- 2019-12-20 CA CA3124100A patent/CA3124100A1/en active Pending
- 2019-12-20 HR HRP20231527TT patent/HRP20231527T1/hr unknown
- 2019-12-20 FI FIEP19842497.0T patent/FI3898638T3/fi active
- 2019-12-20 EA EA202191760A patent/EA202191760A1/ru unknown
- 2019-12-20 PE PE2021000917A patent/PE20211963A1/es unknown
- 2019-12-20 PL PL19842497.0T patent/PL3898638T3/pl unknown
- 2019-12-20 RS RS20231120A patent/RS64900B1/sr unknown
- 2019-12-20 SM SM20230417T patent/SMT202300417T1/it unknown
- 2019-12-20 LT LTEPPCT/US2019/067717T patent/LT3898638T/lt unknown
- 2019-12-20 SI SI201930650T patent/SI3898638T1/sl unknown
- 2019-12-20 PT PT198424970T patent/PT3898638T/pt unknown
- 2019-12-20 CN CN202510888950.0A patent/CN121021534A/zh active Pending
- 2019-12-20 JP JP2021535787A patent/JP7473554B2/ja active Active
- 2019-12-20 KR KR1020217022513A patent/KR20210109559A/ko active Pending
- 2019-12-20 CN CN201980085324.0A patent/CN113227102B/zh active Active
-
2021
- 2021-06-17 CL CL2021001590A patent/CL2021001590A1/es unknown
- 2021-06-17 SA SA521422311A patent/SA521422311B1/ar unknown
- 2021-06-18 CO CONC2021/0008043A patent/CO2021008043A2/es unknown
- 2021-07-20 ZA ZA2021/05115A patent/ZA202105115B/en unknown
-
2024
- 2024-10-08 US US18/908,888 patent/US20250026767A1/en active Pending
-
2025
- 2025-02-26 AU AU2025201372A patent/AU2025201372A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| IL286218A (en) | Solid state forms of ripretinib | |
| EP4007752C0 (en) | Kif18a inhibitors | |
| EP4007753C0 (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| DK4045039T3 (da) | Hæmning af human integrin-alfa4beta7 | |
| EP4007756C0 (en) | KIF18A INHIBITORS | |
| IL277778B (en) | Bcl6 inhibitors | |
| PT3793565T (pt) | Inibidores mcl-1 | |
| EP3833350A4 (en) | Pyrrolopyrimidine itk inhibitors | |
| PL3638666T3 (pl) | Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego | |
| IL290561A (en) | Alkynyl quinazoline compounds | |
| MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3980011C0 (en) | SARM1 HIBITORS | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| EP3976797A4 (en) | ANTI-CRISPR INHIBITORS | |
| DK3826983T3 (da) | Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere | |
| SI3749673T1 (sl) | Kristalinična oblika biktegravir natrija | |
| EP3812456A4 (en) | Growth inhibitor | |
| EP3833374C0 (en) | PROTEASOME INHIBITORS |